Invitation

WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ WELTGESUNDHEITSORGANISATION Date: 13 December 2021 ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ REGIONAL OFFICE FOR EUROPE Ms Elen Ohov BUREAU RÉGIONAL DE L’EUROPE REGIONALBÜRO FÜR EUROPA Adviser ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО European Union Affairs and International Co- Head office: operation Department UN City, Marmorvej 51, Ministry of Social Affairs DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1 Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01 Email: [email protected] 10122 Tallinn Website: http://www.euro.who.int Estonia Our reference: Your reference: Notre référence: Votre référence: Unser Zeichen: Ihr Zeichen: См. наш номер: На Ваш номер: Dear Ms Ohov, Enrolment to Global Antimicrobial Resistance and Use Surveillance System for the antimicrobial medicines consumption data At the Sixty-eighth World Health Assembly held in May 2015, Member States adopted the Global Action Plan on antimicrobial resistance. An important element of the Global Action Plan is monitoring the consumption of antimicrobial medicines. World Health Organization (WHO) launched Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to foster harmonised antimicrobial resistance and use surveillance in all countries and thus inform strategies to contain Antimicrobial resistance (AMR). GLASS has initially focused on surveillance data on human priority bacterial pathogens considered the most significant threat globally. The scope of GLASS is progressively growing, incorporating information on antimicrobial medicines consumption (AMC). WHO invites Estonia to enrol to the Surveillance of Antimicrobial Consumption component of GLASS (GLASS-AMC). As a member of the European Surveillance of Antimicrobial Consumption Network (ESAC-Net) coordinated by the European Centre for Disease Prevention and Control (ECDC), Estonia, as a WHO and EU Member State, already reports AMC data to ECDC via the European Surveillance System (TESSy). In order to avoid double reporting by WHO and EU Member States, ECDC shares the AMC data with WHO under appropriate Data Protection Clauses concluded in 2018 and supplemented in 2020 which extend to all types of transfer of data collected from WHO and EU Member States via TESSy. UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email: [email protected] DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int Denmark With your enrolment to GLASS-AMC, please note the following: 1) Your enrolment is subject to Terms of Use for Global Antimicrobial Resistance and Use Surveillance System Platform (“Terms of Use”) attached to this letter. 2) Subject to the Data Protection Clauses between ECDC and WHO/Europe, ECDC will provide WHO/Europe with Estonia’s AMC data which have been submitted to ECDC via TESSy. 3) AMC data transferred from ECDC to WHO/Europe will be included in the GLASS database. 4) The national approval of AMC data will be granted by the national focal point in the GLASS database. 5) AMC data will be validated collaboratively by the national/area focal point and WHO through the GLASS database. 6) AMC data in the GLASS database will be included in WHO publications and may be further used in accordance with the Terms of Use. 7) Original AMC data of Estonia in the GLASS database will be only accessible by Estonia and WHO. 8) WHO will not share product level consumption data to third parties. Any request by third parties to share these data will be redirected to the GLASS-AMC national focal points. The decision to share as well as data sharing will be under the responsibility of Estonia without involvement of WHO. 9) WHO will establish opt out mechanisms for publication and sharing of other types of information or data at the product or substance levels to allow the Member States to notify WHO on some national legal rules limiting publishing and sharing of AMC data submitted to WHO. 10) Additional information which is not reported to ECDC may be requested by WHO subject to the terms of this letter and the Terms of Use. We kindly ask you to confirm your agreement on enrolment to GLASS-AMC with the above conditions and to provide contact details – name, function, institution, email address, telephone number - of GLASS-AMC focal points for Estonia. For smooth implementation of GLASS-AMC, WHO closely collaborates with ESAC-Net coordinated by ECDC which has national focal points for Estonia. We would like to ask for your consideration to extend the responsibilities of the national focal points, who are currently (and/or will be) appointed with ESAC-Net to enable them to address GLASS-AMC related matters by extending to them the remit of the GLASS-AMC focal points for Estonia. We would very much appreciate receiving this information by 31 January 2022 at the latest to email address: [email protected] (copy to [email protected]). –2– Enquiries should be directed to Ms Kotoji Iwamoto, Technical Officer ([email protected]) in Access to Medicines and Health Products (AMP) Programme, WHO Regional Office for Europe (copy to [email protected], [email protected]). Sincerely yours, Natasha Azzopardi Muscat Director Division of Country Health Policies and Systems Encls: Terms of Use for Global Antimicrobial Resistance and Use Surveillance System Platform Example of letter of enrolment to GLASS-AMC Copy for information to: Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs, Suur-Ameerika 1, 10129 Tallinn, Estonia H.E. Ms Katrin Saarsalu-Layachi, Ambassador Extraordinary and Plenipotentiary, Permanent Representative, Permanent Mission of the Republic of Estonia to the United Nations Office and other international organizations in Geneva, Chemin du Petit-Saconnex 28A, CH-1209 Genève, Switzerland H.E. Mr William Mart Laanemäe, Ambassador Extraordinary and Plenipotentiary, Embassy of the Republic of Estonia, Frederiksgade 19, 4th floor, 1265 Copenhagen K, Denmark Ms Kristina Köhler, Liaison Officer, WHO Country Office, Estonia, Paldiski Road 81, 10617 Tallinn, Estonia –3– World Health Organization Global Antimicrobial Resistance Surveillance System (GLASS) Terms of Use The Global Antimicrobial Resistance Surveillance System (GLASS) collects, analyses and reports back aggregated comparable and validated data on antimicrobial resistance and on the implementation status of national antimicrobial resistance surveillance systems in order to inform decision-making, drive local, national and regional action, and provide the evidence for interventions and advocacy. The World Health Organization (WHO) developed GLASS in accordance with WHA Resolution A68/A/CONF./1 Rev 1 to support the implementation of the Global Action Plan on Antimicrobial Resistance adopted at the Sixty-eight World Health Assembly in May 2015. By accessing the GLASS dedicated and protected internet platform for data collection the national officer mandated to represent the national surveillance programme (hereinafter called “User”) takes note of and accepts the terms of use contained herein. Failure to comply with these terms of use may result in WHO terminating access to the Web-based internet GLASS platform. WHO reserves the right to update these terms of use at any time and without notice and accepts no liability for any error or omissions in this regard. The amended terms of use will automatically be effective when published on the Web-based internet GLASS platform. Data are the basis for all sound public health actions and the benefits of data sharing are widely recognized, including scientific and public health benefits. Whenever possible, WHO wishes to promote the sharing of health data, including but not restricted to surveillance and epidemiological data. In this connection, and without prejudice to information sharing and publication pursuant to legally binding instruments, by providing the Data to WHO through the Web-based GLASS platform, the User confirms and agrees to the following: 1. He/she has the full legal right to share the data with WHO for the purposes described herein. 2. The transfer of the data to WHO and use of the data as provided herein does not and will not violate any intellectual property rights of any third party. 3. The data submitted have been collected in accordance with applicable national laws, including data protection laws aimed at protecting the confidentiality of identifiable persons. 4. WHO is entitled to use the data in any format and in any manner it may wish in line with its public health mandate without having to ask for additional permission. This includes the right for WHO to disseminate the data, incorporate them in any works, and authorize their use to third parties working with WHO. 5. With respect to data submitted to the Antimicrobial Consumption Module, WHO shall use all reasonable efforts to ensure that, any information at product level expressly indicated to 1  WHO as confidential by the User, will not be disclosed, disseminated, or published outside of WHO. 6. WHO will take reasonable measures to ensure appropriate acknowledgement for the provision of the data in accordance with its policies and practices. 7. Access: Access to the Web-based internet GLASS platform requires an electronic identification which consists of user name, password and potentially other security measures. The User is responsible for the safekeeping of this access information. The User may not sell, share or publish their access information. 8. WHO Name and Emblem: Use of the WHO name and emblem is not authorized in connection with any matter relating to this Web-based internet GLASS platform. 9. No WHO warranties: Although all reasonable precautions have been taken to verify the content provided by the Users into the Web-based internet GLASS platform, WHO makes no warranties, express or implied, regarding the content, presentation, appearance, completeness or accuracy of the data in the Web-based internet GLASS platform. 10. Responsibility: WHO shall not be liable for any loss or damage arising directly or indirectly in connection with, or resulting from, the use of the web-based internet GLASS platform. WHO further expressly excludes liability for any indirect, special, incidental or consequential damages which may arise in respect of the Web-based internet GLASS platform and its use, and the results thereof, including, without limitation, any use of the data. 11. Country or area designations: The designations employed in the web- based internet GLASS platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the definition of frontiers and borders. 12. Mentions of companies or products: Any mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. 13. Privileges and Immunities: Nothing contained herein shall be construed as a waiver of any of the privileges and immunities enjoyed by the World Health Organization under national or international law, and/or as submitting the World Health Organization to any national court jurisdiction. Questions Questions relating to the use of Web-based internet GLASS platform or these terms of use can be sent to the following email address: [email protected] 2 Saatja: PANAGIOTAKI, Katerina <[email protected]> Saadetud: 23.12.2021 12:17 Adressaat: Elen Ohov <[email protected]> Koopia: Triin Uusberg <[email protected]>; SM Info <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; <[email protected]>; KÖHLER, Kristina <[email protected]>; GARNER, Sarah <[email protected]>; LINDHARDT, Lisbeth Sjaelborg <[email protected]>; IWAMOTO, Kotoji <[email protected]> Teema: AMC Network - Invitation to GLASS Enrolment Dear Ms Ohov, Please see the attached correspondence sent from the World Health Organization, Regional Office for Europe. One or more attachments may be included. We look forward to hearing from you. With kind regards, Katerina Panagiotaki Access to Medicines and Health Products (AMP) WHO Regional Office for Europe Copenhagen, Denmark Office: 3.3.11 Web: Follow WHO on | | |